Clinics advertise adipose stem cell hair restoration as though the question were settled. The published record does not read that way. This guide covers the registered studies and randomized comparisons behind adipose cell therapy for hair loss, including the two most recent randomized trials, which both came back negative.
TLDR No adipose-derived product is FDA approved for hair loss. In a randomized US trial, the high dose adipose cell arm lost terminal hair and did worse than fat alone. The two most recent randomized comparisons found no benefit over PRP or over a placebo side. Safety signals in small studies have been benign, but efficacy is unproven, and banking adipose tissue does not guarantee eligibility, access, or clinical benefit.
Important Disclaimer: Save My Fat does not provide FDA-approved treatments or cures for any disease, including hair loss and androgenetic alopecia. Banking adipose tissue today does not guarantee eligibility, access, or clinical benefit from any future therapy, clinical trial, or medical program. No adipose-derived stem cell product currently has FDA approval for hair loss. All content is for educational purposes only and does not constitute medical advice. Patients must consult their own licensed healthcare professionals regarding all medical decisions.
The pitch is easy to picture. Studies here take a person’s own fat, or the cell population separated from it, and place it in the scalp. The registered studies behind it are few, small, and mostly finished years ago.
FDA’s roster of approved cellular therapies lists no adipose-derived product for any disease. Save My Fat preserves a patient’s own adipose tissue and is not a clinic or a treatment provider. What follows keeps the negative findings in view.
What adipose cell therapy research on hair loss actually studies
It studies a person’s own fat, or the cells separated from it, placed into the scalp in small early stage studies. Four registered studies fit that description, only one is enrolling, and none supports an approved use.
One completed study enrolled 7 people, three of whom withdrew. Its report of no treatment-emergent adverse events and a 31 percent hair density increase at six months rests on four people analyzed in a single arm with no control group, which leaves it uninterpretable for efficacy.
A second study of point-of-care adipose stromal vascular fraction enrolled 8 people, and its registry record carries no posted results.
The one recruiting study is Phase 1/2, estimates 40 participants at two US sites, and lists hair loss alongside seven other cosmetic endpoints. Recruiting means enrolling, not effective. Anyone weighing participation should ask a licensed physician.
What the STYLE trial actually found
It found no dose-dependent benefit. The arm given the highest dose of adipose cells lost terminal hair over 52 weeks, and it did worse than the arm given fat alone.
STYLE was randomized and blinded, ran at four US sites, enrolled 71 people, and completed in March 2018. The table shows terminal hair count change at 52 weeks in the modified intent to treat Norwood-Hamilton III subgroup that the trial record reports.
| Study arm | Participants | Terminal hair count change at 52 weeks |
|---|---|---|
| Fat plus high dose adipose cells | 16 | minus 5.62 |
| Fat plus low dose adipose cells | 22 | plus 16.2 |
| Fat alone | 24 | minus 0.57 |
| No fat control | 9 | minus 7.92 |
Read the right column downward. More cells produced less hair than fewer cells did, and the highest dose finished below plain fat. An inverted dose response is the signature of noise in a small subgroup, not of a therapeutic effect.
Safety was clean, with zero serious adverse events and zero unanticipated adverse events in all four arms. Benign safety in an early stage 71 person study is not evidence of benefit, nothing tested here is FDA approved, and these numbers are worth reading with a licensed physician.
Both recent randomized comparisons were negative
In the two most recent randomized comparisons, adding adipose cells did not beat what the comparison arm achieved on its own.
The first, in Skin Res Technol in 2024, randomized 18 people, nine per arm, to one adipose stromal vascular fraction injection plus two PRP sessions, or to three PRP injections alone. The PRP comparison found “no significant difference” in the evaluated variables, and the PRP-only group had the greater increase in mean hair count. Its authors wrote that “considering lower cost and greater accessibility of PRP, it can be used before SVF”. At nine per arm, it is severely underpowered.
The second, in Stem Cell Res Ther in 2023, was randomized, double-blind and split-scalp in 37 men, comparing adipose-derived stem cell conditioned media against saline on the other side of the same scalp. Hair count, density and thickness rose significantly on both sides at six weeks. The split-scalp study reported that “No statistically significant differences between treatment groups were found.” Every participant also used 5 percent minoxidil twice daily, which plausibly drove the entire effect.
Both findings are early stage, neither preparation is FDA approved, and a licensed physician is the right person to interpret them.
The positive studies, and what limits each one
The favorable results come from small, short, mostly uncontrolled work, and each one carries a limitation its own authors state.
A 2020 randomized, double-blind, vehicle-controlled study tested an adipose-derived stem cell constituent extract. The topical extract was applied to the scalp rather than injected, so it does not support cell therapy. It randomized 38 people, and 34 completed. Hair count at 16 weeks rose 28.1 percent against 7.1 percent with vehicle, and diameter rose 14.2 percent against 6.3 percent. Three further limits: it ran 16 weeks, it analyzed 34 people, and one author is affiliated with the product company.
A 2023 systematic review screened 140 articles and kept 9, reporting no serious adverse events and increases in hair density. Its stated limitation is blunt: “Standardized protocol was not found.”
A 2026 larger review pooled 20 studies and 724 patients, and those studies are “RCTs, prospective cohorts, case series, pilot studies, and retrospective analyses,” so most are not randomized. Within that mixed evidence it reported density increases of 41 to 48 percent after a single injection, and its authors ask for “larger randomized controlled trials, standardized methodologies, and extended follow-up.” None of it is FDA approved, and none of it replaces a licensed physician.
What FDA approval status means here
No adipose-derived product is FDA approved for hair loss, or for any other disease. There is no separate, easier lane for cosmetic uses.
The only FDA-approved mesenchymal stromal cell product was approved in December 2024. It comes from bone marrow, is indicated for steroid-refractory acute graft-versus-host disease in pediatric patients 2 months and older, and does not validate adipose products.
Stromal vascular fraction, used in much of this hair work, is not a lightly regulated tissue product. FDA’s July 2020 guidance classifies adipose as a structural tissue and calls isolating that fraction “generally considered more than minimally manipulated.” Products that fail those criteria are regulated as a drug, device, or biological product under 21 CFR 1271.20, which requires an investigational new drug application to study one.
FDA’s consumer alert states the rule plainly: “Stem cell products are regulated by FDA, and, generally, all stem cell products require FDA approval.”
How to evaluate a hair restoration claim
Check three things: whether the product is approved, what tissue the cited research used, and whether that research had a control group. Most marketing here fails at least one.
Tissue source is where hair claims go wrong most often. Hair exosome research is dominated by umbilical cord and Wharton’s jelly products, which are not adipose, and no registered trial studies adipose-derived exosomes for androgenetic alopecia. Source tissue shapes cell behavior, so birth tissue results are not adipose evidence.
No listing implies approval. FDA’s patient information page states that “The inclusion of a product in the clinicaltrials.gov database or the fact that a firm has registered with FDA and listed its product does not mean the product is legally marketed.” It adds that if you are charged for these products outside a clinical trial, “you are likely being deceived and offered a product illegally.”
FDA acts on this. A September 2025 warning letter reproduced a firm’s marketed “Ideal Applications,” which included “hair restoration therapies.” Those products were Wharton’s jelly and amniotic fluid plus exosomes, the tissue source problem again.
State law does not change the federal picture. A statute saying a physician may perform an unapproved therapy speaks to medical board discipline, not federal law, and 21 CFR 1271.20 applies in all 50 states. Learning to spot fake clinics and to read trial phase labels helps.
Where adipose tissue banking fits
Banking preserves a person’s own adipose tissue. It is not a treatment, it is not a step toward hair regrowth, and nothing in the record above makes it one.
Save My Fat is a connector. It links patients and providers with a US tissue bank, and it does not collect, process, store, or treat tissue. Banking does not guarantee eligibility, access, or clinical benefit from any future therapy, trial, or program.
Autologous status is also oversold. The exception at 21 CFR 1271.90 removes donor screening and testing for a person’s own cells, and nothing else. Registration, listing, good tissue practice, and labeling still apply. Wider context sits in these hair and skin trials.
Frequently Asked Questions
Is any adipose stem cell hair restoration product FDA approved?
No. FDA’s roster of approved cellular and gene therapy products lists no adipose-derived product for any disease, and none for hair loss. The only approved mesenchymal stromal cell product comes from bone marrow and is indicated for steroid-refractory acute graft-versus-host disease in pediatric patients.
What do the registered trials on ClinicalTrials.gov show?
A small, early field. Four registered studies test a person’s own fat or adipose cells for hair loss. One is recruiting, one enrolled 7 people, one enrolled 8 and posted no results, and the randomized one produced an inverted dose response.
Does banking adipose tissue help with hair loss?
No. Banking is preservation, not a treatment, and it does not connect a patient to any pathway. Efficacy for hair loss is unproven, the two most recent randomized comparisons were negative, and any future use would depend on FDA regulatory status.
Key Takeaways
Adipose-derived cells for hair loss sit in early stage investigation, and efficacy is unproven. The randomized US trial found the high dose cell arm lost terminal hair and finished below fat alone, an inverted dose response that reads as noise. The two most recent randomized comparisons were negative: PRP alone did better in one, and the treated and placebo sides improved equally on minoxidil in the other. The positive results come from small, short, mostly uncontrolled studies whose authors ask for larger randomized trials. No adipose product is FDA approved for hair loss, and banking does not guarantee eligibility, access, or clinical benefit.
Save My Fat operates as a tissue preservation service, not a medical practice or treatment provider. Stem cell and regenerative medicine regulations vary by state, including specific informed-consent and disclosure requirements in Florida, Utah, and Nevada governing tissue and stem cell services. Banking adipose tissue does not connect patients to any treatment pathway, and any future use depends on FDA regulatory status, physician guidance, and the availability of approved or investigational pathways at that time.
Readers weighing adipose tissue banking for potential future use can review current pricing or start a conversation through the contact page.
Save My Fat partners with L2 Bio for laboratory processing and storage.
This article is for educational purposes only and does not constitute medical or legal advice. Legal and medical review including neurology and neurosurgery input is required before publication. Please consult your neurologist or neurosurgeon before making any decisions about adipose tissue banking or research participation.
About the author: Oscar Tellez is the founder and CEO of Save My Fat. He holds a Bachelor of Science in Exercise Science and Health Promotion from Florida Atlantic University. He has spent more than a decade in the regenerative medicine industry across product distribution, laboratory and vendor relationships, and provider training. He is not a licensed clinician, and this article is educational, not medical advice.
Related guide: adipose stem cell trials.
